AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads
Dong-A ST has scored a major early success in its inroads into cancer R&D through a sizable immuno-oncology deal with AbbVie, which also underscores the US firm’s push to expand its assets in the area.
You may also be interested in...
Dong-A ST’s Head of Research Taeyoung Yoon talks to Scrip about the leading South Korean pharma’s ambitions to become a developer of original drugs, its innovative drug R&D strategy, and other major achievements as it reshapes its business.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.